Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Patients with upper gastrointestinal cancers have a poor prognosis and only few treatment options. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid targets in many solid tumours, and they have synergistic effects in preclinical studies.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Acta oncologica (Stockholm, Sweden) |
Vol/bind | 51 |
Udgave nummer | 2 |
Sider (fra-til) | 234-42 |
Antal sider | 9 |
DOI | |
Status | Udgivet - feb. 2012 |
ID: 107123908